April 12th 2022
Paris, April 12, 2022 – 8.00 am (CEST)
CARMAT (FR0010907956, ALCAR), the designer and developer of the world’s most advanced total artificial heart, aiming to provide a therapeutic alternative to people suffering from end-stage biventricular heart failure (the “Company”), today announces the success of its capital increase for a gross amount of €40.5 million, of which €36.5 million for specialized and strategic investors as defined below and €4.1 million for individuals (via the PrimaryBid platform) (the “Global Offering”).
Stéphane Piat, Chief Executive Office of CARMAT, said: “I would like to thank all of our investors, both historical and new, for their contribution to the success of this important financing for CARMAT. The funds raised will allow us to calmly focus, during the coming months, on the resumption of implants of our Aeson® artificial heart, expected in October 2022. I am particularly delighted with the participation of a large number of individual investors, made possible thanks to the PrimaryBid platform. We are very appreciative of their support for CARMAT, a unique French company in the field of medical technologies. Thanks to their support and that of all our other investors, we are one step closer to our goal of making Aeson® the number 1 alternative to a heart transplant, and thus of providing a genuine solution for the many patients suffering from end-stage biventricular heart failure who currently have no therapeutic options.”